Barclays Has Lowered Expectations for Cellectis (NASDAQ:CLLS) Stock Price
Cellectis (NASDAQ:CLLS – Get Free Report) had its target price lowered by Barclays from $5.00 to $4.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 189.86% from the stock’s current […]
More Stories
Bobby Lee’s Net Worth And His Journey To Success
One of the oldest comedians from the US, Bobby Lee, has spent around 30 years in the field of comedy,...
UK Sanctions Russia After Inquiry Holds Putin Responsible for 2018 Novichock Poisonings
By Guy Birchall The UK issued new sanctions on Russia on Dec. 4, after a public inquiry into the death...
Indiana House Passes New Congressional Map Favoring Republicans
By Arjun Singh The Indiana House of Representatives on Dec. 5 passed a bill that would revise the state’s maps...
Economists Forecast Stronger US Growth, Lingering Inflation in 2026
By Tom Ozimek The U.S. economy will grow faster next year than previously projected and inflationary pressures will tick down,...
Noem Says US Travel Ban to Expand to Over 30 Countries
By Aldgra Fredly Homeland Security Secretary Kristi Noem said on Dec. 4 that the Trump administration is looking to increase...
Supreme Court Will Hear Trump’s Birthright Citizenship Case
By Matthew Vadum The U.S. Supreme Court decided on Dec. 5 to review whether President Donald Trump’s executive order ending birthright...